Yasmina M Saade1, Ginger Nicol1, Eric J Lenze1, J Philip Miller2, Michael Yingling1, Julie Loebach Wetherell3, Charles F Reynolds4, Benoit H Mulsant5. 1. Department of Psychiatry, Washington University, St. Louis, Missouri. 2. Division of Biostatistics, Washington University in St. Louis, St. Louis, Missouri. 3. Department of Psychiatry, VA San Diego Healthcare System, University of California, San Diego, California. 4. Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania. 5. Department of Psychiatry, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.
Abstract
OBJECTIVE: The purpose of this study was to examine the influence of comorbid anxiety symptoms on antidepressant treatment remission in older adults with major depressive disorder (MDD). METHOD: In this multisite clinical trial, 468 older adults aged 60 years or older with MDD received open-label protocolized treatment with venlafaxine extended release (ER) titrated to a maximum of 300 mg daily. At baseline, anxiety was assessed with the Anxiety Sensitivity Index, the Brief Symptom Inventory (BSI) anxiety subscale, and the Penn State Worry Questionnaire. To measure treatment response, depressive symptoms and suicidality were assessed every 1-2 weeks with the Montgomery-Asberg Depression Rating Scale and the 19-item Scale for Suicide Ideation; anxiety was assessed with the BSI. Logistic regression and survival analysis were used to evaluate whether anxiety symptoms predicted depression remission. We also examined the relationships between anxiety scores and suicidality at baseline. RESULTS: Baseline anxiety symptoms did not predict remission or time to remission of depressive symptoms. Depressive, worry, and panic symptoms decreased in parallel in patients with high anxiety. Anxiety symptoms were associated with the severity of depression and with suicidality. CONCLUSION: In older adults with MDD, comorbid anxiety symptoms are associated with symptom severity but do not affect antidepressant remission or time to remission.
OBJECTIVE: The purpose of this study was to examine the influence of comorbid anxiety symptoms on antidepressant treatment remission in older adults with major depressive disorder (MDD). METHOD: In this multisite clinical trial, 468 older adults aged 60 years or older with MDD received open-label protocolized treatment with venlafaxine extended release (ER) titrated to a maximum of 300 mg daily. At baseline, anxiety was assessed with the Anxiety Sensitivity Index, the Brief Symptom Inventory (BSI) anxiety subscale, and the Penn State Worry Questionnaire. To measure treatment response, depressive symptoms and suicidality were assessed every 1-2 weeks with the Montgomery-Asberg Depression Rating Scale and the 19-item Scale for Suicide Ideation; anxiety was assessed with the BSI. Logistic regression and survival analysis were used to evaluate whether anxiety symptoms predicted depression remission. We also examined the relationships between anxiety scores and suicidality at baseline. RESULTS: Baseline anxiety symptoms did not predict remission or time to remission of depressive symptoms. Depressive, worry, and panic symptoms decreased in parallel in patients with high anxiety. Anxiety symptoms were associated with the severity of depression and with suicidality. CONCLUSION: In older adults with MDD, comorbid anxiety symptoms are associated with symptom severity but do not affect antidepressant remission or time to remission.
Authors: Eric J Lenze; Benoit H Mulsant; Daniel M Blumberger; Jordan F Karp; John W Newcomer; Stewart J Anderson; Mary Amanda Dew; Meryl A Butters; Jacqueline A Stack; Amy E Begley; Charles F Reynolds Journal: Lancet Date: 2015-09-27 Impact factor: 79.321
Authors: Maurizio Fava; A John Rush; Jonathan E Alpert; G K Balasubramani; Stephen R Wisniewski; Cheryl N Carmin; Melanie M Biggs; Sidney Zisook; Andrew Leuchter; Robert Howland; Diane Warden; Madhukar H Trivedi Journal: Am J Psychiatry Date: 2008-01-02 Impact factor: 18.112
Authors: Eric J Lenze; Benoit H Mulsant; M Katherine Shear; Patricia Houck; Charles F Reynolds III Journal: Drugs Aging Date: 2002 Impact factor: 3.923
Authors: Maud de Feijter; Desana Kocevska; Tessa F Blanken; Isabelle F van der Velpen; M Arfan Ikram; Annemarie I Luik Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2022-06-08 Impact factor: 4.519
Authors: Peter Zhukovsky; Michael Wainberg; Milos Milic; Shreejoy J Tripathy; Benoit H Mulsant; Daniel Felsky; Aristotle N Voineskos Journal: Proc Natl Acad Sci U S A Date: 2022-06-01 Impact factor: 12.779
Authors: Beatrix Krause-Sorio; Prabha Siddarth; Michaela M Milillo; Roza Vlasova; Linda Ercoli; Katherine L Narr; Helen Lavretsky Journal: Front Psychiatry Date: 2020-11-17 Impact factor: 4.157